The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -21.98 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as bioAffinity Technologies, Inc. reports it. History and quarterly detail are in the app.
- Laboratory Services$6.2M
- Health Care, Patient Service$5.0M
- Histology Service Fees$1.1M
- Medical Director Fees$68K
- Other Revenues$5K
Leadership changes
From bioAffinity Technologies, Inc.'s own filings, the day they're filed.
- Roby Joyce · Directors · departureeff. 2026-03-05
- Robert Anderson · Directors · departureeff. 2026-03-05
- Roberto Rios · appointmenteff. 2025-08-12
Latest filings
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-27
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-05-11
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about bioAffinity Technologies, Inc., every answer cited🔒
- The Intelligence Brief — added when bioAffinity Technologies, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.